AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 82 min read$TLRY

Tilray revenue rises as beverage business drives record quarterly sales

Tilray Inc reported Q1 revenue of $257.1M, up 23% YoY, driven by beverage growth. Gross profit rose 35% to $77.5M. Beverage revenue increased 82% to $101.5M, while cannabis revenue fell. Net loss was $40M, with adjusted EBITDA at $9.2M. The company reaffirmed its fiscal 2027 adjusted EBITDA forecast of $68M-$75M.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 3:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray revenue rises as beverage business drives record quarterly sales — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TLRYBearishMed
01

Why it matters

The earnings release shows top‑line growth but bottom‑line weakness, prompting a modest share decline.

02

Market read

First‑quarter earnings provide fresh data for traders; the mixed results suggest short‑term downside with potential upside from beverage growth.

03

What to watch

BrewDog acquisition synergies and strong beverage margins may materialize later in the year.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Tilray is a NASDAQ‑listed cannabis and consumer products company that recently acquired BrewDog to expand its beverage portfolio.

Company-level read

Ticker impact

$TLRYBearishHigh confidence
Context

Tilray reported record Q1 revenue of $257.1M, 23% YoY growth, but net loss of $40M and shares fell ~3% pre‑market.

Expected impact

likely further pressure as market prices in the net loss and weaker EBITDA guidance.

Evidence & confidence

Revenue beat is offset by a larger net loss and a modest guidance reaffirmation, causing the stock to trade down.

Market effects

Sector

Cannabis sector may see broader scrutiny as earnings highlight margin pressure despite revenue growth.

Regional

International expansion in EMEA shows growth but may not offset US market weakness.

Global

Limited; primarily affects Tilray and peers in the cannabis space.

Counterpoint

What could challenge this read

Revenue surge and beverage segment strength could support a rebound if cost controls improve.

Key entities

  • company
    Tilray Inc

    NASDAQ: TLRY, cannabis and consumer products firm.

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

4 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min